http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102265772-B1

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-08
filingDate 2014-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-102265772-B1
titleOfInvention Preparation of tert-butyl 4-((1r,2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2- carboxamido)piperidine-1-carboxylate
abstract The present invention relates to a lactone of formula (III) comprising contacting a lactone of formula (II) with an azacycloalkylamine of formula (II-Am) in the presence of a tertiary amine base followed by contacting with a sulfonyl halide of formula (II-Su) to a process for the preparation of N-protected 6-(piperidin-4-ylcarbamoyl)piperidin-3-yl sulfonate. <Formula III> <Formula II> <Formula II-Am> <Formula II-Su> In the above formula, P G1 and P G2 are amine protecting groups; k, p and q are 0, 1, or 2, and W, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined herein. A further embodiment adds a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octane suitable for use as a β-lactamase inhibitor.
priorityDate 2013-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012053350-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414877687
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1268291
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431579119
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466963890
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467534694
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15540
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID90646663
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467389450
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468384752
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420368670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45258964
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414737218

Total number of triples: 31.